Fresenius Medical Care again included in Dow Jones Sustainability Index
Fresenius Medical Care again included in Dow Jones Sustainability Index
Bad Homburg (December 11, 2023) Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases has been recognized as a sustainability leader with inclusion in the Dow Jones Sustainability Europe Index for the 14th consecutive year.
The DJSI Europe comprises European sustainability leaders as identified by S&P Global through the Corporate Sustainability Assessment.
Helen Giza, CEO of Fresenius Medical Care, said: “Our commitment towards sustainability is a key aspect to being successful in the long-term and creating value for our patients and the communities we serve. We are proud that the DJSI has recognized our efforts to integrate sustainable actions systematically into our company.”
Fresenius Medical Care achieved improvements especially in customer relationship management, and also gained high scores for its focus on labor practices around diversity and inclusion.
You can find an overview of Fresenius Medical Care’s progress in sustainability here.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 3.9 million patients worldwide regularly undergo dialysis treatment. Through its network of 4,014 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately 342,000 patients around the globe and is the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.
